Mersana Therapeutics Nets $35M Investment Led by NEA
March 03, 2015
Mersana Therapeutics has raised $35 million in a Series B1 financing led by New Enterprise Associates. Additional participants included new investor Rock Springs Capital, as well as returning backers Pfizer Venture Investments and Fidelity Biosciences. Mersana engineers antibody-drug conjugates designed to maximize the potential of new and established therapeutic classes. The company will use the new capital to fund the advancement of its pipeline of products; its first investigational new drug filing is anticipated later this year. Mersana previously raised a $12.5 million Series A1 round at a $32 million valuation in August 2012.